Kornimate/medical-research-clean huggingface dataset:
doxorubicin and strontium-89 with or without celecoxib in treating patients with progressive androgen-independent prostate cancer and bone metastases

Conditions: Metastatic Cancer; Prostate Cancer

Summary: rationale: drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. strontium-89 may relieve bone pain caused by prostate cancer. celecoxib may stop the growth of cancer by stopping blood flow to the tumor and by blocking the enzymes necessary for tumor cell growth. combining doxorubicin and strontium-89 with celecoxib may kill more tumor cells. purpose: this randomized phase ii trial is studying celecoxib together with doxorubicin and strontium-89 to see how well they work compared to doxorubicin and strontium-89 alone in treating patients with progressive androgen-independent prostate cancer and bone metastases.

objectives: * compare time to prostate-specific antigen progression in patients with progressive androgen-independent prostate cancer and bone metastases treated with doxorubicin and strontium chloride sr 89 with or without celecoxib. outline: this is a randomized study. patients are stratified according to extent of bone metastases on bone scan (\> 20 lesions vs ≤ 20 lesions) and quality of response (i.e., decline of the prostate-specific antigen from baseline) to prior induction chemotherapy (≥ 80% vs \< 80%). patients are randomized to 1 of 2 treatment arms. * arm i: patients receive doxorubicin iv over 30 minutes on days 1, 8, 15, and 22 and strontium chloride sr 89 iv on day 1. patients also receive oral celecoxib twice daily in the absence of disease progression. * arm ii: patients receive doxorubicin and strontium chloride sr 89 as in arm i. projected accrual: a total of 70 patients (35 per treatment arm) will be accrued for this study within 18 months.

Eligibility criteria:
disease characteristics: * diagnosis of androgen-independent prostate cancer * osteoblastic metastases * no predominant visceral metastases * progressive disease after response to prior induction chemotherapy (prostate-specific antigen decline of at least 50% from baseline after 16 weeks of treatment) * no symptomatic lymphadenopathy (i.e., scrotal or pedal edema) patient characteristics: age * any age performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * adequate physiologic reserves prior concurrent therapy: biologic therapy * not specified chemotherapy * see disease characteristics endocrine therapy * not specified radiotherapy * no prior radionuclide therapy surgery * not specified other * no more than 3 prior cytotoxic treatments * more than 6 months since prior celecoxib or rofecoxib

Keywords: recurrent prostate cancer stage iv prostate cancer bone metastases progressive androgen-independent prostate cancer metastron sr-89 strontium-89 strontium chloride sr 89 celecoxib celebrex doxorubicin rubex adriamycin
carestream vue pacs v12.1.5 ct perfusion clinical protocol

Conditions: Ischemia

Summary: the purpose of this clinical study is to evaluate the carestream vue pacs 12.1.5 computed tomography (ct) perfusion ("investigational device") imaging performance. evaluation of ct perfusion (ctp) imaging will compare ctp with the predicate device, the olea sphere pacs with ct perfusion module.

this study will demonstrate the imaging performance ctp by an assessment of 30 ctp de-identified patient cases collected retrospectively. the purpose of the study is to demonstrate equivalent clinical quality between the investigational and predicate devices using a radiologist evaluation of key metrics which are applicable to ctp images. the maps include the following: * mean transfer time (mtt) - the time that the contrast material stays in the tissue * cerebral blood volume (cbv) - the volume of blood that is in a known volume of the tissue based on the concentration of contrast material that is in the tissue over the time * cerebral blood flow (cbf) - describes the flow of the blood to the affected tissue * time to peak (ttp) - the time that maximum enhancement is achieved at each volume of the tissue * time to maximum of impulse response function (tmax) the retrospective data collected for each patient will include a non-contrast head ct exam completed on the same day as ctp image, and a follow-up head ct at least 1-2 days after the initial imaging study (initial non-contrast head ct) if available. similar performance between the investigational and predicate devices was demonstrated by the following criteria. i. substantial equivalence of the perfusion maps between devices ii. substantial equivalence of the core and penumbra tissues resulting from thresholds on the perfusion maps between devices iii. the clinical decision based on the exclusion or inclusion criteria for treatment is equivalent between devices

Eligibility criteria:
inclusion criteria: * retrospective patient ctp cases with case maps that include the following information: mtt, cbv, cbf, ttp, and tmax. * initial ct exam and ct exam 1-2 days after the initial exam if available, and * retrospective ctp case with subject/patient 18 years of age or older exclusion criteria: * low quality images, or images that are not clinically acceptable for clinical diagnostic reading as determined by the principal investigator, * subject less than 18 years of age
impact of transjugular intrahepatic portosystemic shunts on liver stiffness

Conditions: Portal Hypertension; Liver Fibroses

Summary: pilot study examining changes in liver stiffness measured by ultrasound before and after tips creation

single arm pilot study of adults ≥18yo investigating changes in liver stiffness as measured by ultrasound acoustic radiation force impulse (arfi) before and after creation of tips. duration of participation is 30 days from tips creation. tips creation with viatorr stent graft will be in accordance with its fda-approved indication for symptomatic portal hypertension and per the manufacturer's instructions for use. liver stiffness will be measured on pre-tips and post-tips ultrasounds using phillips epiq ultrasound systems equipped with elastpq ultrasound shear wave elastography. both ultrasounds will be performed at times which are standard of care before and after tips creation. primary objectives include liver stiffness as measured by ultrasound acoustic radiation force impulse (arfi) before and after creation of tips. secondary objectives include change in portosystemic gradient, clinical success as measured by difference in frequency of repeat paracentesis post-tips or freedom from recurrence of variceal bleeding and rate of hepatic encephalopathy. exploratory objectives include serum biomarkers of liver stiffness.

Eligibility criteria:
inclusion criteria: * symptomatic portal hypertension secondary to cirrhosis undergoing elective outpatient tips * age \>18, age \<80 * capable of giving informed consent exclusion criteria: * coagulopathy defined as international normalized ration (inr) \>2 which cannot be corrected with fresh frozen plasma * platelet count \<50,000/microliter, which cannot be corrected with platelet transfusion * bmi \>35 and/or cirrhosis due to non-alcoholic steatohepatitis (due to inaccurate elastography measurements in patients with fatty liver) * urgent or emergent tips for bleeding * portal vein thrombosis with in the main, 1st, or 2nd order branches of the portal vein * hepatic vein thrombosis (ie no budd chiari syndrome) * excessive alcohol use defined as more than 2 oz in 24 hours on any individual day within the last 30 days * inability to provide informed consent * pregnant or nursing women * enrollment in concurrent therapeutic trial for symptomatic portal hypertension
artificial intelligence (ai) technology may help patients to understand bowel preparation better before they go for colonoscopy.this study attempts to leverage ai chatbot in counselling patients to improve bowel cleanliness, reduce anxiety as well as increase procedural satisfaction

Conditions: Colorectal Cancer Screening; Colon Polyps and Adenomas; Bowel Preparation Quality; Artificial Intelligence (AI)

Summary: traditional pre-colonoscopy counselling requires significant time from healthcare workers to explain procedures, limiting efficiency and patient turnover. inadequate bowel preparation exacerbates this issue, leading to repeat procedures and increased costs. however, no study has yet evaluated the effectiveness of ai in improving the boston bowel preparation scale (bbps) for colonoscopy preparation. by addressing this gap, ai chatbots could provide personalized guidance, reduce healthcare worker burden, improve preparation quality, and enhance patient experience.this research attempts to evaluate the effectiveness of using artificial intelligence (ai) chat bot to improve bowel preparation, anxiety level and patient's satisfaction among colonoscopy patients in hospital tuanku muhriz (hctm), compared to conventional instructions


Eligibility criteria:
inclusion criteria: * all scheduled colonoscopy with indication * adequate digital literacy * adequate language literacy with malay and english language exclusion criteria: * patients with memory impairment due to previous stroke, dementia or alzheimer's disease * diagnosed with clinical anxiety

Keywords: colorectal cancer colon polyp colonoscopy bowel preparation boston bowel preparation score (bbps) artificial intelligence aichatbot large language model patient satisfaction cancer screening
expanded access protocol of 68ga-psma-11 for pet imaging

Conditions: Prostate Cancer

Summary: to provide expanded access to 68ga-psma-11 pet imaging for eligible participants to detect and localize prostate cancer for initial and subsequent treatment strategy.

prostate-specific membrane antigen (psma) targeted positron emission tomography (pet) imaging has been embraced enthusiastically worldwide. given the unmet clinical need for accurately diagnosing and staging prostate cancer and the encouraging results of 68ga-psma-11 pet worldwide, university of california los angeles (ucla) and university of california san francisco (ucsf) conducted pivotal registration trials to assess 68ga-psma-11's safety and efficacy profile in detecting prostate cancer in adult patients. to gap the unmet clinical need of 68ga-psma-11 pet during the period prior to fda approval, ucla nuclear medicine offers expanded access of this investigational pet drug to eligible participants.

Eligibility criteria:
biochemical recurrent (i. inclusion/exclusion) and preprostatectomy (ii. inclusion/exclusion) staging patients will be eligible for the expanded access protocol. in order to be eligible to participate in this study, an individual must meet the following criteria: biochemical recurrence population: i. inclusion criteria: * histopathological proven prostate adenocarcinoma. * rising prostatic specific antigen(psa) after definitive therapy with prostatectomy or radiation therapy. * post radical prostatectomy (rp) * psa equals to or greater than 0.2 ng/ml measured more than 6weeks after rp * post-radiation therapy -astro-phoenix consensus definition * nadir + greater than or equal to 2 ng/ml rise in psa * karnofsky performance status of ≥ 50 (or eastern cooperative oncology group (ecog)/ world health organization (who) equivalent). * age \> 18. * ability to understand a written informed consent document, and the willingness to sign it. i. exclusion criteria: * concomitant investigational therapy. * known inability to lie flat, remain still or tolerate a pet scan. * patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer. preprostatectomy staging population: ii. inclusion criteria: * biopsy proven prostate adenocarcinoma. * considered for prostatectomy with lymph node dissection. * intermediate to high-risk disease (as determined by elevated psa \[psa\>10\], t-stage \[t2b or greater\], gleason score \[gleason score \> 6\] or other risk factors). * able to provide written consent. * karnofsky performance status of ≥50 (or ecog/who equivalent). ii. exclusion criteria: * patients not capable of getting pet study due to weight, claustrophobia, or inability to lay still for the duration of the exam. * neoadjuvant chemotherapy, radiation therapy or any definitive local therapy prior to prostatectomy including focal ablation techniques (hifu).

Keywords: prostate imaging
peripheral nerve stimulation of genicular nerves versus conventional therapy with intra-articular steroid injection for chronic knee pain: a prospective, randomized pilot study

Conditions: Peripheral Nerve Stimulation; Genicular Nerves; Chronic Knee Pain

Summary: to compare the effects of the following types of therapy on knee range of motion when given to patients with chronic knee pain: * a standard steroid injection * peripheral nerve stimulation (pns) therapy in combination with a standard steroid injection * pns therapy in combination with a placebo injection steroid injections are given directly into the knee joints and are considered to be the standard therapy for chronic knee pain. in this study, the injection will be made of the steroid drugs triamcinolone and bupivacaine.

primary objectives: * to compare the mean change in knee range of motion using goniometry from at 30 days (visit 2) from baseline among the three treatment arms. secondary objectives: * to compare the mean change in knee range of motion using goniometry at 60 days (visit 3) and 90 days (visit 4) from baseline among the three treatment arms. * to compare changes in knee pain scores (nrs), womac index, use of opioids (measured in morphine milliequivalent), and incidence of complications and adverse effects at 30 days, 60 days, and 90 days from baseline among the three treatment arms

Eligibility criteria:
inclusion criteria: * patients diagnosed with chronic knee pain (baseline pain score \>=4), seen at pain management center at md anderson cancer center; if patient has bilateral knee pain, the side with the more severe knee pain will be treated first and counted towards the primary and secondary endpoints * patients between ages 18-85 years old * patient signed informed consent exclusion criteria: * patients with cognitive dysfunction or without capacity to consent * patient with recent history (\<6 months) of drug or alcohol abuse * patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection * patients with allergies to local anesthesia, steroids, or adhesives * patients who are on opioids for reasons other than knee pain
the amenorrhea with etonogestrel implant

Conditions: Contraception

Summary: the etonogestrel subdermal implant has been available worldwide for more than 15 years. the action of etonogestrel subdermal implant is principal via suppression of ovulation, but it also has effects on cervical mucus and in some women induces suppression of endometrial proliferation. several studies have confirmed its high efficacy and convenience. the uterine bleeding problems and in particular irregular bleeding and amenorrhea are major side effects of etonogestrel subdermal implant. a considerable number of patients request early removal due to bleeding changes. amenorrhea occurs in about 22% in etonogestrel subdermal implant users. despite the presence of many studies that reported the prevalence of etonogestrel subdermal implant-associated bleeding, little is known about the predictive factors affecting menstrual bleeding patterns especially amenorrhea after etonogestrel subdermal implant insertion. these predictive factors should be provided prior to the etonogestrel subdermal implant insertion which may improve acceptance and continuation of etonogestrel subdermal implant.


Eligibility criteria:
inclusion criteria: 1. women aged between 18 and 40 years. 2. women who are not lactating. 3. non-pregnant women 4. women have regular menstrual cycles every 21-35 days with a typical cycle length variation of no more than 5 days. 5. women who will esi only for pregnancy prevention for at least 12 months. 6. have not any medical or gynecologic problems. exclusion criteria: 1. women with any contraindications for progesterone-only contraception in accordance with who eligibility criteria. 2. refuse participation in the study.
acupuncture in myasthenia gravis (acumg)

Conditions: Myasthenia Gravis

Summary: the purpose of the study is to determine the effect acupuncture treatment on individuals with a diagnosis of myasthenia gravis (mg). a total of 20 people with mg will be enrolled in this study to receive acupuncture treatment 2 times a week for 12 weeks. participants will be randomized into two groups: 1) immediate start and 2) delayed start (12 weeks). the delayed start group will act as a control group for the first 12 weeks, but then receive acupuncture treatment for 12 weeks. it is hypothesized that patients with mg who receive acupuncture treatment will have improved quality of life and activities of daily living compared to no treatment.


Eligibility criteria:
inclusion criteria: * ability to provide and provision of signed and dated informed consent form * age 18-80 * diagnosis of mg exclusion criteria: * non-english speaking * participation in acupuncture treatment outside of the study, while enrolled * history of any other serious neurological, psychiatric, chronic pain disorders, or seizures * history of bleeding diathesis, other bleeding disorders, or syncope with needle puncture * history of cardiac arrhythmia or current pacemaker, neurostimulator, or other implanted stimulation device * recent or active substance use disorder * women who are currently pregnant, lactating, or planning to become pregnant during the study * any other medical conditions that could affect their ability to participate in acupuncture treatments for the study duration (as determined by study investigators) * active participation or past participation ≤3 months in any other interventional study. * unwilling to participate in all study related activities
resistance to oral therapy in lung cancer

Conditions: Non Small Cell Lung Cancer

Summary: in the management of non-small cell lung cancer of the adenocarcinoma type, different therapeutic strategies can be proposed. these strategies are defined according to the results of a biological analysis of blood and/or tissue samples from the lung tumor. mutations in the tumor dna are sought. thus, patients with sensitizing mutations can benefit from a treatment with a 3rd generation tyroine kinase inhibitor (tki) whose efficacy has been widely demonstrated. patients without tumor mutations will not benefit. however, resistance to tkis appears after a certain time, often linked to the appearance of new mutations in the tumor. for this reason, blood biologic analyses are regularly performed to search for the emergence of resistance mutations and to propose a therapeutic alternative as soon as possible. these analyses are performed routinely in the laboratory. in the course of these analyses, the investigators have identified conventional mutations but also new mutations not previously described in the literature. our objective is to list all the molecular abnormalities revealed during blood biological analyses, to determine their frequency and to study whether certain abnormalities can be linked to resistance to tki.


Eligibility criteria:
inclusion criteria: * advanced non-small cell lung cancer stage iiib/iv * documentation of activating egfr mutations (exon 19 deletions or exon 21 l858r substitution mutations) at the time of initial diagnosis * patient may receive up to one line of third egfr tki * plasma sample testing performed to detect egfr tki resistance exclusion criteria: * patients have other concurrent cancers * patients who are not eligible receive tki

Keywords: 3rd tyrosine kinase inhibitor cell free dna mutations
surgical or non-surgical treatment of plantar fasciitis

Conditions: Fasciitis, Plantar, Chronic

Summary: plantar fasciitis (pf) is one of the most common causes of heel pain in 40-60 year old people. approximately 10% of the population is affected by the disorder and the pf prevalence is 3.6-7.0%. the risk factors include decreased ankle dorsiflexion, overweight (bmi\> 27), pronated foot position, and prolonged work and activity-related weight bearing. the condition affects both active and less active people. the typical symptoms are pain around the attachment of the foot's tendon mirror (fascia plantaris), especially the medial part. the pain is well defined and occurs during weight bearing activities or during the first steps after rest. the walking pattern is changed to relieve pain. ultrasound scan is used to confirm the diagnosis (thickened tendon mirror\> 4 mm). the condition is described as inflammatory, but the relationship between the initial inflammatory condition and the chronic tendon mirror overload injury (fasciopathy) is unknown and marked by degenerative changes. although the majority of people improve within 1-2 years, the long-term prognosis is unknown. people with symptoms lasting \> 7 months have poor prognosis and should be offered other treatment. non-surgical treatment is often first line of treatment followed by surgical treatment. in this clinical trial investigators compare pain levels (fhsq-dk) in people, who receive surgical treatment (radiofrequency microtenotomy, shoe inserts and patient education) and people who receive non-surgical treatment (strength training, shoe inserts and patient education) with a primary end-point at 6 months. the hypothesis is that surgical treatment is better than non-surgical treatment measured by fhsq-dk (pain)

to be completed later

Eligibility criteria:
inclusion criteria: * vas pain score \> 30 within last 7 days * plantar heel pain\> 7 months * palpation soreness fascia plantaris at heel * plantar heel pain during first steps (first-step sign) * read and understand danish exclusion criteria: * systemic diseases or neuropathy * diabetes * pregnant * previous heel surgery on same foot * cortisone injections within past 3 months * bilateral symptom onset within past 7 days * signs of tarsal tunnel * facia plantaris thickness of less than 4 mm * performed message / head recovery / stretching within the past month * any treatment for plantar pain within the past 3 months * other reasons
implementation of physical exercise at the workplace (irma10) - occupational load

Conditions: Musculoskeletal Disorders; Stress

Summary: static postures, repetitive work tasks, and work stress increase the risk for musculoskeletal disorders and sickness absence. objective measurements of occupational loadings - emg for muscular activity, eeg for cognitive activity, ecg for cardiovascular activity and heart rate variability, actigraphy for bodily movements - may provide useful early indicators of muscular, cognitive and cardiovascular overload. the aim of this study is to investigate the effect of an individually tailored bio-psycho-social intervention strategy versus "usual care" ergonomics and standard physical exercises (reference group) on these risk factors in lab technicians with a history of work-related musculoskeletal pain.


Eligibility criteria:
inclusion criteria: * laboratory technician * pain intensity \>= 3 (scale of 0-10) * pain duration \>= 3 months * pain frequency \>= 3 days per week exclusion criteria: * life threatening disease * pregnancy